Related Experiment Video
Updated: Aug 5, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Hemodynamic effects of nitroglycerin combined with diltiazem in patients with coronary artery disease
Insights
The combination of diltiazem and nitroglycerin effectively reduces myocardial oxygen demand in patients with coronary heart disease. This drug combination maintains coronary blood flow without increasing heart rate, suggesting a beneficial therapeutic approach.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary heart disease (CHD) poses significant risks.
- Understanding hemodynamic effects of cardiovascular drugs is crucial.
Purpose of the Study:
- To evaluate the combined hemodynamic effects of intravenous diltiazem and nitroglycerin in CHD patients.
- To compare the combination therapy with monotherapy using either diltiazem or nitroglycerin.
Main Methods:
- Studied 12 patients with CHD receiving intravenous diltiazem and nitroglycerin combination.
- Compared results with 7 patients on diltiazem alone and 5 on nitroglycerin alone.
- Monitored coronary and left ventricular hemodynamics, including blood pressure, heart rate, and cardiac output.
Main Results:
- The diltiazem-nitroglycerin combination significantly reduced systolic blood pressure (27%) and rate-pressure product (22%).
- Left ventricular end-diastolic pressure (-36%) and dp/dt (-6.4%) decreased, while coronary flow and cardiac output were maintained.
- Combination therapy showed greater reduction in myocardial oxygen demand compared to monotherapy, without increasing heart rate.
Conclusions:
- Diltiazem and nitroglycerin combination therapy offers superior reduction in myocardial oxygen demand than individual drugs.
- This combination maintains coronary blood flow and cardiac output without adverse increases in heart rate.
- The diltiazem-nitroglycerin combination shows potential for managing myocardial ischemia and warrants further investigation.
Abstract:
Resting coronary and left ventricular hemodynamic effects of diltiazem and nitroglycerin, given intravenously in combination, were studied in 12 patients with coronary heart disease. Results observed with this combination were compared with those in seven patients given diltiazem initially (group I) and five patients given nitroglycerin initially (group II). The diltiazem-nitroglycerin combination reduced systolic blood pressure 27 percent (p less than or equal to 0.05) with no significant change in heart rate to affect a 22 percent (p less than or equal to 0.05) decrease in the rate-pressure product. Left ventricular end-diastolic pressure (-36 percent) and dp/dt (-6.4 percent) both declined (p less than or equal to 0.05). Coronary flow and cardiac output were both maintained. Diltiazem alone and nitroglycerin alone also reduced systolic pressure and the rate-pressure product but to a lesser degree than the combination. Diltiazem did not significantly affect left ventricular end-diastolic pressure and dp/dt. Nitroglycerin reduced left ventricular end-diastolic pressure to an extent similar to the reduction produced by the combination but increased heart rate whereas this determinant of myocardial oxygen demand did not increase significantly with the combination. These findings suggest that the combination of diltiazem and nitroglycerin produces a greater reduction in myocardial oxygen demand than either drug alone. In addition, the combination maintains coronary blood flow without increases in determinants of myocardial oxygen demand. This potentially beneficial drug combination warrants further trial in patients with myocardial ischemia.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Vasodilators
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

